Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin

American Journal of Hematology

Volumn 70, Issue 2, 2002, Pages 92-99

  Hasselbalch, Hans Carl ^a,c   Clausen, Nielsaage Tøffner ^b   Anker, Bjarne ^b  

^a Rigshospitalet   (Denmark)

^b HILLERØD HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Anemia; Idiopathic myelofibrosis; Recombinant human erythropoietin

Indexed keywords

ALPHA INTERFERON; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; AUTOIMMUNITY; BLOOD TRANSFUSION; BONE MARROW CELL; CHRONIC DISEASE; CLINICAL ARTICLE; COLLAGEN METABOLISM; ERYTHROID CELL; ERYTHROPOIESIS; FEMALE; HEMODILUTION; HUMAN; IDIOPATHIC DISEASE; MALE; MYELOFIBROSIS; PRIORITY JOURNAL; TREATMENT FAILURE;

AGED; AGED, 80 AND OVER; ANEMIA; BLOOD TRANSFUSION; DANAZOL; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN, RECOMBINANT; FEMALE; HEMOGLOBINS; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; MYELOFIBROSIS;

EID: 0036100832     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajh.10076     Document Type: Article

References (22)

1. Idiopathic myelofibrosis: Pathogenesis, natural history, and management
2. Leritropoietina umana ricombinante in ematologia
3. New trends in the treatment of myelofibrosis with myeloid metaplasia
4. Recombinant human erythropoietin in patients with myelodysplastic syndrome and myelofibrosis
5. Recombinant human erythropoietin therapy in patients with myelofibrosis with myeloid metaplasia
6. Recombinant human erythropoietin for the treatment of anemia in myelofibrosis with myeloid metaplasia
7. Recombinant human erythropoietin in the treatment of cancer-related anaemia
8. Use of recombinant human erythropoietin outside the setting of uremia
9. rHuEpo for the treatment of anemia in myelofibrosis with myeloid metaplasia. Experience in 6 patients and meta-analytical approach
10. Recombinant erythropoietin can be an effective agent in transfusion-dependent myelofibrosis
11. A new approach with rHuEpo in the treatment of myelodysplastic syndromes (MDS) and idiopathic myelofibrosis
12. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Results of a phase I/II clinical trial
13. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders
14. Hematopoetic growth factors in primary and therapy-related bone marrow insufficiency
15. Erythropoitin treatment of idiopathic myelofibrosis
16. Resolution of transfusion dependence by recombinant human erythropoitin (rHuEPO) in acquired pure red cell aplasia (PRCA) associated with myeloid metaplasia
17. Combination therapy with recombinant human erythropoietin, interferon α-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis
18. Serum erythropoietin in patients with myelofibrosis with myeloid metaplasia
19. International scoring system for evaluating prognosis in myelodysplastic syndromes
20. Adverse effect of erythropoietin in myeloproliferative disorders
21. Treatment of anemia in myelodysplastic syndromes with granulocyte colonystimulating factor plus erythropoietin: Results from a randomized phase II study and long-term follow-up of 71 patients
22. Prognostic factors in idiopathic mylofibrosis. A simple scoring system with prognostic significance